ClinicalTrials.gg
CompletedNCT03347188Updated Dec 13, 2022Results posted

A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH)

A Phase 2 interventional study of Fremanezumab and Placebo in Post-Traumatic Headache, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 33 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-12-13.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 64 studies in Post-Traumatic Headache with a site in United States — 11 open to participants now, 12 under way, none of them phase 3. Post-Traumatic Headache · United States.

Enrollment
17th of 57
87 · median 36
Started
2017
with 4 others
Phase 2
9 of 64
4 open now
Registered
22nd of 64
by date

Among the 64 studies in Post-Traumatic Headache with a site in United States, this one is the 17th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2017, is one of 9 in phase 2, and was the 22nd registered.

Post-Traumatic Headache

192 studies on the registry are indexed under Post-Traumatic Headache; 54 are open to participants now.

Browse Post-Traumatic Headache studies →

Open to participants now

11 of the 64 studies in Post-Traumatic Headache with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Post-Traumatic Headache studies recruiting now, 5 (17%) set no upper age limit and 24 (80%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Post-Traumatic Headache with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety and efficacy of fremanezumab in adult participants aged 18 to 70 years, inclusive, for the prevention of PTH. The study will include a double-blind (DB) treatment period (12 weeks) and an open-label (OL) treatment period (12 weeks).

03

Conditions studied

  • Post-Traumatic Headache

Keywords

  • posttraumatic headache (PTH)
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has a body weight greater than or equal to (≥) 45 kilograms (kg).
  • Traumatic injury to the head has occurred, defined as a structural or functional injury resulting from the action of external forces.
  • The participant has a diagnosis of PTH.
  • The participant is not using preventive medications for headache.
  • Women of whose male partners are potentially fertile (that is, no vasectomy) must use highly effective methods for the duration of the study and for 30 weeks after the last study drug administration. Men must be sterile or, if they are potentially fertile or reproductively competent (that is, not surgically or congenitally sterile) and their female partners are of childbearing potential, must use, together with their female partners, acceptable birth control methods for the duration of the study and for 30 weeks after the last study drug administration.

NOTE- Additional criteria apply, please contact the investigator for more information.

Exclusion criteria

Exclusion Criteria:

  • The participant has a previous history of brain imaging showing evidence of intracerebral hemorrhage, subdural or epidural hematomas, or subarachnoid hemorrhage as a consequence of the traumatic head injury. Brain images with structurally insignificant changes, as discussed and approved by the sponsor, will be reviewed by the sponsor on a case-by-case basis.
  • The participant has PTH attributed to craniotomy.
  • The participant has whiplash and subsequent headache but no history of head injury or concussion.
  • The participant is using analgesic medications containing opioids (including codeine) or a barbiturate on average more than 15 days per month.
  • The participant has had exposure to a monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) pathway (erenumab, eptinezumab, galcanezumab, and fremanezumab) during the 6 months prior to the day of the screening visit.
  • The participant is currently being treated with onabotulinumtoxinA (for example, Botox, Dysport, Xeomin) application in the head or neck or received any such injection during the 3 months prior to the screening visit.
  • The participant has been implanted with any electronic devices for headache prevention during the 3 months prior to the screening visit or is currently using any implanted or externally applied stimulator or device.
  • The participant has been treated with a nerve block for head and/or neck during the 3 months prior to the screening visit.
  • The participant is a pregnant or lactating woman or plans to become pregnant during the study.

NOTE- Additional criteria apply, please contact the investigator for more information.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Fremanezumab

    Participants will receive fremanezumab 675 milligrams (mg) administered as 3 subcutaneous (SC) injections (225 mg/1.5 milliliters \[mL\] each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.

    Drug: Fremanezumab

  • Placebo comparator
    Placebo

    Participants will receive placebo matching to fremanezumab administered as 3 SC injections (1.5 mL each) at randomization (Week 0), Weeks 4, and 8 during the DB treatment period. Participants who complete the DB treatment period and continue into the OL treatment period will receive fremanezumab 675 mg administered as 3 SC injections (225 mg/1.5 mL each) at Weeks 12, 16, and 20 during the OL treatment period.

    Drug: Placebo

Interventions

  • Fremanezumab will be administered per dose and schedule specified in the arm.

    Also known as: TEV-48125

  • DrugPlacebo

    Placebo matching to fremanezumab will be administered per schedule specified in the arm.

06

What researchers measure

Primary outcomes

  1. DB Period: Mean Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Treatment Period After the First Dose of Fremanezumab

    A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. Least square (LS) mean was calculated using analysis of covariance (ANCOVA) model with the duration of post traumatic headache history (less than 12 month since the brain injury or greater or equal to 12 month since the brain injury) and treatment as fixed effects and the baseline monthly average number of headache days of at least moderate severity as a covariate.

    Time frame: Baseline (Day -28 to Day -1), up to Week 12

Secondary outcomes

  1. DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in Monthly Average Number of Headache Days of Any Severity During 12-Week Treatment With Fremanezumab

    Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.

    Time frame: Baseline (Day -28 to Day-1) up to Week 12

  2. DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During 12-Week Treatment With Fremanezumab

    A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.

    Time frame: Baseline (Day -28 to Day-1) up to Week 12

  3. DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During First 4-Week (Month 1), 5- to 8-Week (Month 2), and 9- to 12-Week (Month 3)

    A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.

    Time frame: Baseline (Day -28 to Day-1) up to Months 1, 2, and 3

  4. DB Period: Change From Baseline in the Number of Headache Days of At Least Moderate Severity During the First 4-Week (Month 1), 5- to 8-Week (Month 2), and 9- to 12-Week (Month 3)

    A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. LS mean was calculated using ANCOVA model with the duration of post traumatic headache history (less than 12 month since the brain injury or greater or equal to 12 month since the brain injury) and treatment as fixed effects and the baseline monthly average number of headache days of at least moderate severity as a covariate. This approach was used in generating the LS mean values only and was not considered to be an additional statistical analysis, no additional statistical analyses are reported for this outcome measure.

    Time frame: Baseline (Day -28 to Day -1), up to Months 1, 2, and 3

  5. DB Period: Change From Baseline in Disability Score, as Measured by the 6-Item Headache Impact Test (HIT-6) Total Score at Week 12 After the First Dose of Fremanezumab

    HIT-6 is a tool used to measure the impact headaches have on a participant's normal daily life and ability to function. The HIT-6 consists of 6 items, including pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress. Each item was answered on a 5-point Likert scale (6=never, 8=rarely, 10=sometimes, 11=very often, or 13=always), which were summed to produce a total score that ranged from 36 to 78, with larger scores reflecting greater impact of headache on the daily life of the participant.

    Time frame: Baseline (Day -28 to Day -1), Week 12

  6. DB Period: Number of Participants (Responder and Non-Responder) With the Patient Global Impression of Change (PGIC) Scale at Weeks 4, 8, and 12 After the First Dose of Fremanezumab

    The PGIC scale is a validated generic tool for the assessment of overall change in the severity of illness following treatment. Participants rated how they felt during assigned time points compared with how they felt before receiving study drug on a 7-point scale, where 1 = No change (or it got worse); 2 = Almost the same, hardly any change at all; 3 = A little better, but no noticeable change; 4 = Somewhat better, but the change has not made any real difference; 5 = Moderately better, and a slight but noticeable change; 6 = Better, and a definite improvement that has made a real and worthwhile difference; and 7 = A great deal better, and a considerable improvement that has made all the difference. Responders were those with a scale of 5 to 7 and non-responders were those with a scale of 1 to 4.

    Time frame: Weeks 4, 8, and 12

  7. DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring at or after the first dose of the study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Baseline (Day -28 to -1) up to Week 12

  8. OL Period: Number of Participants With TEAEs

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring at or after the first dose of the study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Week 12 up to Week 24

  9. DB Period: Number of Participants Who Did Not Complete the Study

    Number of participants who did not complete the study due to any reason and due to AEs are reported.

    Time frame: Baseline (Day -28 to Day -1) up to Week 12

  10. OL Period: Number of Participants Who Did Not Complete the Study

    Number of participants who did not complete the study due to any reason and due to AEs are reported.

    Time frame: Week 12 up to Week 24

  11. DB Period: Number of Participants Who Received Concomitant Medications

    Concomitant medications included: agents acting on renin-angiotensin system, analgesics, anesthetics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antidiarrheals, intestinal antiinflammatory/antiinfective agents, antiemetics and antinauseants, antiepileptics, antifungals for dermatologiocal use, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatics, antineoplastic agents, antiobesity preparations, antipruritics, antithrombotics, antivirals for systemic use, beta blocking agents, calcium channel blockers, cardiac therapy, corticosteroids, cough and cold preparations, diuretics, lipid modifying agents, nasal preparations, thyroid therapy, urologicals, vaccines, psycholeptics, psycoanaleptics, ophthalmologicals, general nutrients, mineral supplements, muscle relaxants, vitamins, drugs used in diabetes, sex hormones and modulators of the genital system, immunosuppresants, drugs for acid related disorders etc.

    Time frame: Baseline (Day -28 to Day -1) up to Week 12

  12. OL Period: Number of Participants Who Received Concomitant Medications

    Concomitant medications included: agents acting on renin-angiotensin system, analgesics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antiemetics and antinauseants, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatics, antineoplastic agents, antithrombotics, beta blocking agents, calcium channel blockers, corticosteroids for systemic use, cough and cold preparations, diuretics, lipid modifying agents, nasal preparations, other gynecologicals, other nervous system drugs, thyroid therapy, unspecified herbal and traditional medicine, urologicals, vaccines, psycholeptics, psycoanaleptics, general nutrients, mineral supplements, muscle relaxants, vitamins, sex hormones and modulators of the genital system, drugs for acid related disorders, drugs for constipation, drugs for obstructive airways disease etc.

    Time frame: Week 12 up to Week 24

  13. Number of Participants With Positive Findings on Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)

    eC-SSRS is a questionnaire to assess suicidal ideation (severity and intensity) and behavior. Suicidal ideation: A series of 1 -5 questions (with 'yes' or 'no' response) with 5 types of ideation of increasing severity: 1. wish to be dead, 2. non-specific active suicidal thoughts, 3. active suicidal ideation with any methods (not plan) without intent to act, 4. active suicidal ideation with some intent to act, without specific plan, 5. active suicidal ideation with specific plan and intent. A positive finding was defined as a 'yes' response to question 4 or 5.

    Time frame: Baseline (Day -28 to Day -1) up to Week 24

  14. Number of Participants With Treatment-Emergent Antidrug Antibodies (ADA)

    Number of participants with treatment-emergent antidrug antibodies reported.

    Time frame: Baseline (Day -28 to Day -1) up to Week 24

07

Results

Posted Mar 26, 2021

Participant flow

Double-blind (DB) Period (12 Weeks)
Participant flow — Double-blind (DB) Period (12 Weeks)
MilestoneFremanezumabPlacebo
Started4443
Received at least 1 dose of study drug4343
Full analysis set (fas)4243
Completed2926
Not completed1517
Withdrew: Protocol violation22
Withdrew: Withdrawal by subject48
Withdrew: Lost to follow-up74
Withdrew: Adverse event11
Withdrew: Other than specified12
Open-label (OL) Period (12 Weeks)
Participant flow — Open-label (OL) Period (12 Weeks)
MilestoneFremanezumabPlacebo
Started3535
Entered in ol period for anti-drug antibody (ada) only2628
Received at least 1 dose of study drug97
Completed86
Not completed2729
Withdrew: Entered for ada assessment only, not treated2628
Withdrew: Withdrawal by subject10
Withdrew: Other than specified01

Outcome measures

PrimaryDB Period: Mean Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Treatment Period After the First Dose of Fremanezumab

A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. Least square (LS) mean was calculated using analysis of covariance (ANCOVA) model with the duration of post traumatic headache history (less than 12 month since the brain injury or greater or equal to 12 month since the brain injury) and treatment as fixed effects and the baseline monthly average number of headache days of at least moderate severity as a covariate.

Time frame:
Baseline (Day -28 to Day -1), up to Week 12
Reported as:
Least squares mean · days
DB Period: Mean Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Treatment Period After the First Dose of Fremanezumab
daysFremanezumabPlacebo
DB Period: Mean Change From Baseline in Monthly Average Number of Headache Days of at Least Moderate Severity During the 12-Week Treatment Period After the First Dose of Fremanezumab-3.6 ± 0.99-5.1 ± 1.01
Statistical analysis
  • Fremanezumab vs Placebo · ANCOVA · p = 0.1876 (Threshold for significance at 0.05 level.) · Ls mean: 1.5 · 95% CI -0.73 to 3.67
SecondaryDB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in Monthly Average Number of Headache Days of Any Severity During 12-Week Treatment With Fremanezumab

Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.

Time frame:
Baseline (Day -28 to Day-1) up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in Monthly Average Number of Headache Days of Any Severity During 12-Week Treatment With Fremanezumab
ParticipantsFremanezumabPlacebo
DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in Monthly Average Number of Headache Days of Any Severity During 12-Week Treatment With Fremanezumab54
SecondaryDB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During 12-Week Treatment With Fremanezumab

A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.

Time frame:
Baseline (Day -28 to Day-1) up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During 12-Week Treatment With Fremanezumab
ParticipantsFremanezumabPlacebo
DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During 12-Week Treatment With Fremanezumab911
SecondaryDB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During First 4-Week (Month 1), 5- to 8-Week (Month 2), and 9- to 12-Week (Month 3)

A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28.

Time frame:
Baseline (Day -28 to Day-1) up to Months 1, 2, and 3
Reported as:
Count of participants · Participants
DB Period: Number of Participants Reaching at Least 50% Reduction From Baseline in the Monthly Average Number of Headache Days of at Least Moderate Severity During First 4-Week (Month 1), 5- to 8-Week (Month 2), and 9- to 12-Week (Month 3)
ParticipantsFremanezumabPlacebo
Month 1811
Month 2814
Month 31412
SecondaryDB Period: Change From Baseline in the Number of Headache Days of At Least Moderate Severity During the First 4-Week (Month 1), 5- to 8-Week (Month 2), and 9- to 12-Week (Month 3)

A headache day was defined as a day when a participant reported a headache of at least moderate severity. Monthly averages were derived and normalized to 28 days equivalent by the following formula: (number of days of efficacy variable over relevant period/number of days with assessments recorded in the e-diary over the relevant period) \* 28. The change was calculated as post-baseline value - baseline value. LS mean was calculated using ANCOVA model with the duration of post traumatic headache history (less than 12 month since the brain injury or greater or equal to 12 month since the brain injury) and treatment as fixed effects and the baseline monthly average number of headache days of at least moderate severity as a covariate. This approach was used in generating the LS mean values only and was not considered to be an additional statistical analysis, no additional statistical analyses are reported for this outcome measure.

Time frame:
Baseline (Day -28 to Day -1), up to Months 1, 2, and 3
Reported as:
Least squares mean · days
DB Period: Change From Baseline in the Number of Headache Days of At Least Moderate Severity During the First 4-Week (Month 1), 5- to 8-Week (Month 2), and 9- to 12-Week (Month 3)
daysFremanezumabPlacebo
Change at Month 1-3.6 ± 0.97-4.0 ± 0.99
Change at Month 2-3.7 ± 1.06-6.7 ± 1.06
Change at Month 3-5.2 ± 1.20-7.2 ± 1.21
SecondaryDB Period: Change From Baseline in Disability Score, as Measured by the 6-Item Headache Impact Test (HIT-6) Total Score at Week 12 After the First Dose of Fremanezumab

HIT-6 is a tool used to measure the impact headaches have on a participant's normal daily life and ability to function. The HIT-6 consists of 6 items, including pain, social functioning, role functioning, vitality, cognitive functioning, and psychological distress. Each item was answered on a 5-point Likert scale (6=never, 8=rarely, 10=sometimes, 11=very often, or 13=always), which were summed to produce a total score that ranged from 36 to 78, with larger scores reflecting greater impact of headache on the daily life of the participant.

Time frame:
Baseline (Day -28 to Day -1), Week 12
Reported as:
Least squares mean · units on a scale
DB Period: Change From Baseline in Disability Score, as Measured by the 6-Item Headache Impact Test (HIT-6) Total Score at Week 12 After the First Dose of Fremanezumab
units on a scaleFremanezumabPlacebo
DB Period: Change From Baseline in Disability Score, as Measured by the 6-Item Headache Impact Test (HIT-6) Total Score at Week 12 After the First Dose of Fremanezumab-6.9 ± 4.54-10.8 ± 4.65
SecondaryDB Period: Number of Participants (Responder and Non-Responder) With the Patient Global Impression of Change (PGIC) Scale at Weeks 4, 8, and 12 After the First Dose of Fremanezumab

The PGIC scale is a validated generic tool for the assessment of overall change in the severity of illness following treatment. Participants rated how they felt during assigned time points compared with how they felt before receiving study drug on a 7-point scale, where 1 = No change (or it got worse); 2 = Almost the same, hardly any change at all; 3 = A little better, but no noticeable change; 4 = Somewhat better, but the change has not made any real difference; 5 = Moderately better, and a slight but noticeable change; 6 = Better, and a definite improvement that has made a real and worthwhile difference; and 7 = A great deal better, and a considerable improvement that has made all the difference. Responders were those with a scale of 5 to 7 and non-responders were those with a scale of 1 to 4.

Time frame:
Weeks 4, 8, and 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants (Responder and Non-Responder) With the Patient Global Impression of Change (PGIC) Scale at Weeks 4, 8, and 12 After the First Dose of Fremanezumab
ParticipantsFremanezumabPlacebo
Week 4 — Responder1211
Week 4 — Non-Responder2426
Week 4 — Missing66
Week 8 — Responder1417
Week 8 — Non-Responder2021
Week 8 — Missing85
Week 12 — Responder1116
Week 12 — Non-Responder2016
Week 12 — Missing1111
SecondaryDB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring at or after the first dose of the study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Baseline (Day -28 to -1) up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsFremanezumabPlacebo
DB Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)3135
SecondaryOL Period: Number of Participants With TEAEs

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were defined as AEs occurring at or after the first dose of the study drug. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
OL Period: Number of Participants With TEAEs
ParticipantsFremanezumabPlacebo
OL Period: Number of Participants With TEAEs86
SecondaryDB Period: Number of Participants Who Did Not Complete the Study

Number of participants who did not complete the study due to any reason and due to AEs are reported.

Time frame:
Baseline (Day -28 to Day -1) up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants Who Did Not Complete the Study
ParticipantsFremanezumabPlacebo
Discontinued study due to any reason1517
Discontinued study due to AEs11
SecondaryOL Period: Number of Participants Who Did Not Complete the Study

Number of participants who did not complete the study due to any reason and due to AEs are reported.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
OL Period: Number of Participants Who Did Not Complete the Study
ParticipantsFremanezumabPlacebo
Discontinued study due to any reason11
Discontinued study due to AEs00
SecondaryDB Period: Number of Participants Who Received Concomitant Medications

Concomitant medications included: agents acting on renin-angiotensin system, analgesics, anesthetics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antidiarrheals, intestinal antiinflammatory/antiinfective agents, antiemetics and antinauseants, antiepileptics, antifungals for dermatologiocal use, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatics, antineoplastic agents, antiobesity preparations, antipruritics, antithrombotics, antivirals for systemic use, beta blocking agents, calcium channel blockers, cardiac therapy, corticosteroids, cough and cold preparations, diuretics, lipid modifying agents, nasal preparations, thyroid therapy, urologicals, vaccines, psycholeptics, psycoanaleptics, ophthalmologicals, general nutrients, mineral supplements, muscle relaxants, vitamins, drugs used in diabetes, sex hormones and modulators of the genital system, immunosuppresants, drugs for acid related disorders etc.

Time frame:
Baseline (Day -28 to Day -1) up to Week 12
Reported as:
Count of participants · Participants
DB Period: Number of Participants Who Received Concomitant Medications
ParticipantsFremanezumabPlacebo
DB Period: Number of Participants Who Received Concomitant Medications4342
SecondaryOL Period: Number of Participants Who Received Concomitant Medications

Concomitant medications included: agents acting on renin-angiotensin system, analgesics, anti-parkinson drugs, antianemic preparations, antibacterials for systemic use, antiemetics and antinauseants, antihistamines for systemic use, antihypertensives, antiinflammatory and antirheumatics, antineoplastic agents, antithrombotics, beta blocking agents, calcium channel blockers, corticosteroids for systemic use, cough and cold preparations, diuretics, lipid modifying agents, nasal preparations, other gynecologicals, other nervous system drugs, thyroid therapy, unspecified herbal and traditional medicine, urologicals, vaccines, psycholeptics, psycoanaleptics, general nutrients, mineral supplements, muscle relaxants, vitamins, sex hormones and modulators of the genital system, drugs for acid related disorders, drugs for constipation, drugs for obstructive airways disease etc.

Time frame:
Week 12 up to Week 24
Reported as:
Count of participants · Participants
OL Period: Number of Participants Who Received Concomitant Medications
ParticipantsFremanezumabPlacebo
OL Period: Number of Participants Who Received Concomitant Medications97
SecondaryNumber of Participants With Positive Findings on Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)

eC-SSRS is a questionnaire to assess suicidal ideation (severity and intensity) and behavior. Suicidal ideation: A series of 1 -5 questions (with 'yes' or 'no' response) with 5 types of ideation of increasing severity: 1. wish to be dead, 2. non-specific active suicidal thoughts, 3. active suicidal ideation with any methods (not plan) without intent to act, 4. active suicidal ideation with some intent to act, without specific plan, 5. active suicidal ideation with specific plan and intent. A positive finding was defined as a 'yes' response to question 4 or 5.

Time frame:
Baseline (Day -28 to Day -1) up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Positive Findings on Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)
ParticipantsFremanezumabPlacebo
Number of Participants With Positive Findings on Electronic Columbia Suicide Severity Rating Scale (eC-SSRS)00
SecondaryNumber of Participants With Treatment-Emergent Antidrug Antibodies (ADA)

Number of participants with treatment-emergent antidrug antibodies reported.

Time frame:
Baseline (Day -28 to Day -1) up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Antidrug Antibodies (ADA)
ParticipantsFremanezumabPlacebo
Number of Participants With Treatment-Emergent Antidrug Antibodies (ADA)00

Adverse events

Collected over Baseline (Day -28 to Day -1) up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fremanezumab0/43 (0%)2/43 (4.7%)28/43 (65.1%)
Placebo0/43 (0%)1/43 (2.3%)29/43 (67.4%)
Most frequent serious events
Most frequent serious events
EventFremanezumabPlacebo
Gastrointestinal haemorrhageGastrointestinal disorders1/430/43
Non-cardiac chest painGeneral disorders0/431/43
CholelithiasisHepatobiliary disorders0/431/43
Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/430/43
HypotensionVascular disorders1/430/43
Most frequent other events
Showing 10 of 14
Most frequent other events
EventFremanezumabPlacebo
Injection site indurationGeneral disorders18/4314/43
Injection site painGeneral disorders14/4315/43
Injection site erythemaGeneral disorders11/4314/43
HeadacheNervous system disorders6/432/43
Upper respiratory tract infectionInfections and infestations1/435/43
NauseaGastrointestinal disorders4/432/43
Injection site pruritusGeneral disorders4/432/43
NasopharyngitisInfections and infestations2/434/43
SinusitisInfections and infestations4/433/43
International normalised ratio increasedInvestigations4/431/43

Baseline characteristics

Intent-to-treat (ITT) analysis set included all randomized participants.

Age, Continuous
Age, Continuous(years)FremanezumabPlaceboTotal
Mean42.6 ± 13.0143.8 ± 14.4843.2 ± 13.68
Sex: Female, Male
Sex: Female, Male(Participants)FremanezumabPlaceboTotal
Female252550
Male191837
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)FremanezumabPlaceboTotal
Hispanic or Latino448
Not Hispanic or Latino403878
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FremanezumabPlaceboTotal
Race — White413980
Race — Black or African American314
Race — Native Hawaiian or other Pacific Islander011
Race — Other022
Number of Headache Days of at Least Moderate Severity
Number of Headache Days of at Least Moderate Severity(days)FremanezumabPlaceboTotal
Mean18.7 ± 7.0318.5 ± 6.1218.6 ± 6.56
08

Study locations

33 sites
  • Teva Investigational Site 14065
    Phoenix, Arizona 85018, United States
  • Teva Investigational Site 14069
    Scottsdale, Arizona 85259-5452, United States
  • Teva Investigational Site 14048
    Little Rock, Arkansas 72205, United States
  • Teva Investigational Site 30236
    Little Rock, Arkansas 72205, United States
  • Teva Investigational Site 14052
    Long Beach, California 90806, United States
  • Teva Investigational Site 14053
    Los Angeles, California 90073, United States
  • Teva Investigational Site 14060
    San Diego, California 92161, United States
  • Teva Investigational Site 14054
    San Francisco, California 94109, United States
  • Teva Investigational Site 14045
    Fairfield, Connecticut 06824, United States
  • Teva Investigational Site 14063
    Miami, Florida 33136, United States
  • Teva Investigational Site 14041
    North Miami, Florida 33161, United States
  • Teva Investigational Site 14056
    Tampa, Florida 33609, United States
  • Teva Investigational Site 14057
    Riverwoods, Illinois 60015, United States
  • Teva Investigational Site 14067
    Indianapolis, Indiana 46256, United States
  • Teva Investigational Site 14058
    Louisville, Kentucky 40207, United States
  • Teva Investigational Site 14061
    Waltham, Massachusetts 02451, United States
  • Teva Investigational Site 14051
    Kansas City, Missouri 64128-2226, United States
  • Teva Investigational Site 14046
    Saint Louis, Missouri 63141, United States
  • Teva Investigational Site 14043
    Springfield, Missouri 65810, United States
  • Teva Investigational Site 14119
    Albany, New York 12208, United States
  • Teva Investigational Site 14229
    Amherst, New York 14226, United States
  • Teva Investigational Site 14118
    Bronx, New York 10467, United States
  • Teva Investigational Site 14047
    New York, New York 10021, United States
  • Teva Investigational Site 14114
    Durham, North Carolina 27713, United States
  • Teva Investigational Site 14059
    Salisbury, North Carolina 28144, United States
  • Teva Investigational Site 14049
    Portland, Oregon 97225, United States
  • Teva Investigational Site 14064
    Philadelphia, Pennsylvania 19107, United States
  • Teva Investigational Site 14040
    Pittsburgh, Pennsylvania 15236, United States
  • Teva Investigational Site 14230
    Nashville, Tennessee 37203, United States
  • Teva Investigational Site 14055
    Dallas, Texas 75390-8565, United States
  • Teva Investigational Site 14050
    Waco, Texas 76711, United States
  • Teva Investigational Site 14113
    Spokane, Washington 99202, United States
  • Teva Investigational Site 14044
    Morgantown, West Virginia 26506, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Mar 2020, 26 months.

Results were first posted in Mar 2021, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2017
First posted
Nov 20, 2017
StartActual
Dec 18, 2017
Primary completionActual
Mar 13, 2020
CompletionActual
Jun 3, 2020
Results first posted
Mar 26, 2021
Last update
Dec 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03347188
Responsible party
Sponsor
First posted
Nov 20, 2017
Start date
Dec 18, 2017
Primary completion
Mar 13, 2020
Completion
Jun 3, 2020
Results posted
Mar 26, 2021
Last update
Dec 13, 2022

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fremanezumab

Start the discussion